A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: JNJ-88549968
DRUG: Ruxolitinib
DRUG: Momelotinib

Sponsor

Janssen Research & Development, LLC